Ameluz in superficial basal-cell carcinoma: clearance, recurrence and the drug–device regimen

Disease subtype and local treatment

This application concerns superficial basal-cell carcinoma, not every basal-cell cancer and not melanoma. The trial used clinically and histologically confirmed superficial lesions. The distinction matters because a surface-directed intervention cannot be assumed to control deeper or more aggressive growth patterns merely because the visible skin lesion improves. Histology is therefore part of the evidentiary definition rather than an optional cosmetic check. [1] [3]

Clinical interpretation: the therapeutic objective is durable local tumor control while limiting treatment burden and tissue injury. A favorable appearance alone does not establish eradication. Conversely, a biopsy finding without whole-lesion clinical assessment can miss residual disease elsewhere. The trial’s composite endpoint deliberately requires both perspectives, making it more stringent than a simple visual response percentage.

Drug–device exposure and comparator

Ameluz photodynamic therapy was paired with the BF-RhodoLED lamp. Patients received two treatments one to two weeks apart, with another cycle after three months if necessary. The comparator also underwent placebo photodynamic treatment. This assesses the contribution of the active formulation within a defined light-delivery procedure; it is not a direct comparison with surgical excision or Mohs surgery. [1] [3]

Interpretation: treatment success depends on the complete procedure, including lesion preparation, application and illumination. Changing the light source or shortening a cycle cannot be assumed equivalent. Repeat treatment also matters to patient experience: the final clearance endpoint may follow more than the initial two sessions. A readable report should preserve that sequence rather than imply that the reported result follows one uncomplicated application.

Randomized clearance evidence

ALA-BCC-CT013 randomized 187 patients: 145 to active therapy and 42 to placebo. The primary target-lesion composite was evaluated 12 weeks after the start of the final treatment cycle. The observed contrast was large, but about one third of active-treated participants did not meet that strict endpoint. Both the magnitude of benefit and the remaining incomplete-clearance fraction belong in the interpretation. [1]

The release contains a numerical inconsistency for placebo clinical-only clearance: it prints 21.4% together with 8/42, although eight divided by 42 is 19.0%. That row is not used for inference here. The internally consistent composite and histological results are shown below. Identifying a source inconsistency is preferable to silently choosing whichever number makes the contrast look stronger.

Recurrence and endpoint interpretation

A short-term clearance assessment and a recurrence assessment answer different questions. Recurrence must specify the population at risk: all randomized patients, those initially cleared, or individual lesions. A high disease-free proportion among initial responders can coexist with a lower overall success rate when initial nonresponders are retained. These quantities should not be combined without an explicit estimand. [1] [3]

The topline announcement anticipated one-year follow-up, but a complete arm-level recurrence and rescue-treatment dataset is not reproduced in these sources. Consequently, this report does not claim equivalence to surgery or permanent cure. Salvage excision, additional topical treatment and missing follow-up should be counted transparently in any subsequent integrated effectiveness analysis, rather than treating them as ordinary censoring without consequence.

Procedure tolerability and safety completeness

The public efficacy release does not provide the complete randomized adverse-event table. Patient satisfaction is reported, but satisfaction is not a substitute for pain intensity, erythema, treatment interruption or serious adverse-event frequencies. No unreported safety category is assigned a zero rate. The drug–device nature of the intervention makes procedural tolerability an integral part of treatment assessment. [1] [3]

Analytical judgment: willingness to repeat treatment depends on the entire course, not just the final photograph. The trial should distinguish expected local reactions from events requiring medical intervention, and report whether discomfort compromised illumination or completion of the second session. Such interruptions could connect tolerability directly to residual tumor, making separate efficacy and safety headlines misleading without participant-level disposition.

sNDA interpretation and operational follow-through

The reported target decision date is September 28, 2026. The meaningful output is the authorized lesion type, anatomical scope, treatment schedule and follow-up language, not simply an approval headline. Existing experience in actinic keratosis does not automatically establish the same effectiveness or surveillance needs in a confirmed malignancy. The cancer indication must stand on its own evidence. [2] [3]

For management execution, protocol training, device availability and consistent post-treatment surveillance are clinically relevant. The appropriate continuing research question is whether community delivery preserves the trial’s histological control, especially in patients needing repeat cycles. It is not justified to infer a comparative advantage over every established local therapy from this placebo-controlled dataset alone.

Durable local control also requires distinguishing initial clearance from later recurrence. A negative assessment at the protocol visit cannot be extrapolated into a lifetime cure fraction without longitudinal follow-up.

September 14: approval announced; label evidence added

Biofrontera announced FDA approval for adult superficial basal cell carcinoma on September 14, ahead of the previously tracked September 28 PDUFA target. The History date records the announcement; an exact earlier agency action date is not inferred. The September 2026 FDA label confirms Ameluz 10% with BF-RhodoLED or RhodoLED XL photodynamic therapy for adults with sBCC. This does not extend to every BCC subtype or melanoma. [4] [5]

Label Trial 4 (NCT03573401) randomized and treated 187 participants: 145 with Ameluz and 42 with vehicle. Ages ranged from 33 to 89, mean 63; all participants were White, and Fitzpatrick skin types V and VI were not represented. The regimen used two sessions one to two weeks apart, with another two-session cycle for incompletely resolved lesions around three months. The trial used up to 2 g per session, three-hour occlusion and 37 J/cm² illumination; the label's general maximum application amount is a different dosing statement.

Label correction: clinical clearance is not histological clearance

The old evidence tables above are retained as dated source versions. FDA Table 4 distinguishes the main target lesion from all target lesions, and clinical appearance from histology. The September 14 company announcement calls all-target clinical clearance 83%; the label gives 119/145 (82%) for that endpoint and 121/145 (83%) for main-target clinical clearance. Use the label's endpoint-specific counts for current interpretation rather than silently merging these statements. [4] [5]

The label's clinical-clearance placebo numerator is 9/42 (21%), resolving the older report's internally inconsistent 8/42 and 21.4% statement for that endpoint. Among 119 clinically clear Ameluz recipients, 26 (22%) had residual disease on histology. Apparent visual clearance therefore cannot be described as proven eradication, surgical equivalence or permanent cure. The label calls for examination four to six weeks after each cycle and routine skin examinations every six to twelve months.

sBCC safety from FDA Table 2

All 145 active-treated participants in Trial 4 had at least one application-site reaction. The table supplies arm-specific counts for the reported local events. It does not provide a complete sBCC all-cause TEAE, SAE, death or adverse-event discontinuation table. In particular, the nearby label statements about 15% stopping illumination and 41% severe pain concern actinic keratosis studies and must not be imported into this sBCC population. [4] [5]

Trial 5 adds 110 sBCC recipients with qualitatively consistent safety, but does not provide a comparable complete arm table here. Analytical judgment: approval resolves the immediate regulatory question while leaving the practical burden of repeated procedures, pain and confirmation of histological clearance central to implementation. It does not establish relative efficacy against excision.

Sources / References

1. Biofrontera · ALA-BCC-CT013 topline results · October 31, 2024
2. Biofrontera · Q2 2026 update and sNDA schedule
3. Biofrontera AG · 2024 annual report: sBCC development
4. Biofrontera · FDA approval announcement · September 14, 2026 · SEC Exhibit 99.1
5. FDA · Ameluz prescribing information · revised September 2026 · Tables 2 and 4